Read about our COVID-19 Response.

Cerus Corporate Site
  • Home
  • About Cerus
    • Mission and Values
    • Blood Matters
    • Leadership
    • Board of Directors
    • Map and Directions
  • Products
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
      • Annual Meeting
      • Events & Webcasts
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Stock Information
        • Stock Information
      • Analyst Coverage
    • Governance
      • Corporate Governance
    • Resources
      • Email Subscription
      • Investor Contact
  • Learn
    • Newsroom
    • Webinars and Podcasts
    • Insights: Blog
  • Careers
    • Careers
Select Page
  • Home
  • About Cerus
    • Mission and Values
    • Blood Matters
    • Leadership
    • Board of Directors
    • Map and Directions
  • Products
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
      • Annual Meeting
      • Events & Webcasts
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Stock Information
        • Stock Information
      • Analyst Coverage
    • Governance
      • Corporate Governance
    • Resources
      • Email Subscription
      • Investor Contact
  • Learn
    • Newsroom
    • Webinars and Podcasts
    • Insights: Blog
  • Careers
    • Careers
Cerus Websites
  • Cerus.com
  • INTERCEPT-USA.com
  • HCP.INTERCEPT-USA.com
  • INTERCEPT-Canada.com
  • INTERCEPTBloodSystem.com
  • INTERCEPT-Cryoprecipitation.com
  • Cerus.com

    The corporate website includes broad information about Cerus, resources for investors, and career opportunities.
  • INTERCEPT-USA.com

    For residents of the United States – Blood centers and transfusion services will find topics related to the production of pathogen reduced products.
  • HCP.INTERCEPT-USA.com

    For residents of the United States – Hospital blood banks and healthcare practitioners will find content related to clinical topics, implementation, and education.
  • INTERCEPT-Canada.com

    For residents of Canada – Specific information for pathogen reduced platelets and plasma including package inserts.
  • INTERCEPTBloodSystem.com

    Visitors in Europe, the Middle East, Africa, Asia or Latin America will find information about pathogen inactivated platelets and plasma.
  • INTERCEPT-Cryoprecipitation.com

    For residents of the United States – Learn more about the INTERCEPT® Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex.

Latest insights on bacterial contamination in platelet concentrates

by tkirkman | Mar 23, 2021 | Webinars

Sepsis Webinar Series: Part 1 Are you aware of the continuing risk of septic transfusion reactions?We will bring you up to date with the latest, most relevant insights in a series of short educational webinars hosted by experts to cover three key subjects: Latest...

Recent Posts

  • The Lifeblood of Preparedness
  • Latest insights on bacterial contamination in platelet concentrates
  • Highlights from the Annual AABB 2020 Virtual Meeting
  • Are You Ready to Meet the FDA’s Platelet Safety Guidance Deadline?
  • PODCAST: “Preparing Our Blood Supply for the Next Pandemic” with Dr. Susan Stramer

Recent Comments

    Global Headquarters

    1220 Concord Avenue

    Concord, CA US 94520

    +1 925.288.6000

    European Headquarters

    Stationsstraat 79-D

    3811 MH Amersfoort, Netherlands

    +31 (0) 33 49 60 600

    • Cookie Notice
    • Legal
    • Privacy Policy
    • New Federal Laws Affect Health Insurance
    Copyright (c) 2022 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0
    About Cerus
    About Cerus

    Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn.